According to Krishan, the stock is a 'buy' at the current level, with a target price of Rs 640 and a stop loss of Rs 595. It ...

Glenmark Pharmaceuticals, an India-based drug manufacturer has issued a voluntary recall affecting nearly 1.48 million bottles of atomoxetine, a generic medication used to treat ADHD.

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 1380.8, up 3.49% on the day as on 12:49 IST on the NSE. The stock is up 49.05% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in ...

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has ...

The Nifty Pharma index closed on a negative note on Tuesday. Shares of Biocon Ltd.(up 3.2 per cent), Laurus Labs Ltd.(up 3.16 ...

The shares of pharma and IT companies tumbled on March 4 as US President Donald Trump's tariffs on Canada and Mexico came ...

Net Sales at Rs 3,387.55 crore in December 2024 up 35.14% from Rs. 2,506.70 crore in December 2023. Quarterly Net Profit at ...

Glenmark Pharmaceuticals has launched injection Acetylcysteine in the US after acquiring its abbreviated new drug application ...

Glenmark Pharma, Wendt, Uno Minda and Time Technoplast will be some of the other stocks to watch before going into trade.

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to ...

Glenmark’s Acetylcysteine Injection (DEL) is approved based on the safety and efficacy derived from the reference drug ...